Jessica Veloza, APRN
Family · Tallahassee, FLNPI 1215639943
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Viiv Healthcare Company at 26.8% of the total. 2025 is the largest year on record at $788, more than ten times the $17 reported in 2023.
Across 28 payments — averaging $37.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$280
- Merck$187
- Gilead$183
- Teva Pharmaceuticals USA, Inc.$114
- Lilly USA, LLC$95
- Medline Industries LP$52
- plus $132 from 4 others
What the payments were for
- Food & beverage$1,043100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 5 | $280 |
| Merck | 10 | $187 |
| Gilead | 3 | $183 |
| Teva Pharmaceuticals USA, Inc. | 1 | $114 |
| Lilly USA, LLC | 1 | $95 |
| Medline Industries LP | 1 | $52 |
| Novo Nordisk | 2 | $41 |
| Pfizer | 2 | $38 |
| Exact Sciences | 2 | $34 |
| Galderma Laboratories, L.p. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$123
- Austedo XR$114
How this compares
$1,043 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $9,738 |
| Hydroxyzine Hcl | 12 | $511 |
| Famotidine | 15 | $180 |
| Atorvastatin Calcium | 19 | $178 |
| Gabapentin | 12 | $114 |
| Lisinopril | 19 | $80 |
| Hydrochlorothiazide | 20 | $68 |
| Amlodipine Besylate | 19 | $67 |
| Losartan Potassium | 12 | $62 |
| Furosemide | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other family in Tallahassee
- Kathleen WilsonTallahassee$154K
- Brittany YatesTallahassee$73K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.